Mesa Laboratories Inc (MLAB) — 13F Filings Explorer (Q2 2026)

MLAB ranks #3545 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MLAB is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

MLAB is a top-conviction position for Long Path Partners LP — at 20.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Long Path Partners LP has added to its MLAB position for two straight quarters, increasing it by $29.7M to reach $47.5M today.

Barclays PLC has trimmed its MLAB position for two straight quarters, cutting it by $560.1K while still holding $82.5K.

MLAB is up 4.1% today, and institutions have been net buyers of $70.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MLAB posted net income of $4.8M over the trailing twelve months, and currently trades at a P/E of 151.5.

• Profitable — net income of $4.8M over the trailing twelve months
• Revenue grew 3.0% year over year
• Net income improved year over year, from -$620.0K to $4.8M
• Generated $42.8M in positive operating cash flow
• Current ratio of 1.72x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.30x equity — within a conventional range